Osteoporosis (due To Estrogen Deficiency)

Osteoporosis linked to estrogen deficiency arises primarily in postmenopausal women, where declining ovarian estrogen accelerates bone resorption over formation, leading to porous, fragile bones. Up to 20% bone loss occurs during menopause transition, with annual losses of 1-5% thereafter, heightening hip, spine, and wrist fracture risks.?

Pathophysiology

Estrogen normally inhibits osteoclast activity via RANKL/OPG regulation and promotes osteoblast function; its deficiency boosts cytokines like IL-6, TNF, and RANKL, enhancing osteoclastogenesis and turnover imbalance. This results in net bone demineralization, exacerbated by age-related factors, low peak bone mass, or early menopause.?

Risk Factors and Diagnosis

Key risks include early menopause, family history, smoking, low calcium/vitamin D, and sedentary lifestyle; diagnosis uses DEXA scan with T-score ≤ -2.5 indicating osteoporosis. FRAX tool assesses 10-year fracture probability.?

Prevention and Treatment

Lifestyle measures emphasize weight-bearing exercise, calcium (1200 mg/day), vitamin D (800-2000 IU), and fall prevention; pharmacotherapy includes bisphosphonates, denosumab, or hormone therapy for high-risk cases under 60. Monitoring BMD guides therapy duration.